Novo Nordisk Taps Ascendis For Development Of A Once-Monthly GLP-1 Agonist

Extends TransCon Platform Into Metabolic Diseases

 
• By Mandy Jackson

Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.

Once-monthly injections would have a convenience advantage over available once-weekly obesity drugs (Shutterstock)

More from Deals

More from Scrip